Key Highlights

  • Compass Pathways (NASDAQ:CMPS) reported a third-quarter 2026 net loss of USD 9.8 million on November 3, 2026, helped by a USD 40.8 million non-cash gain on Warrant liabilities.
  • Cash and equivalents reached USD 444.0 million at September 30, 2026, up from USD 149.6 million at December 31, 2025, and the company expects that to fund operations into 2028.
  • The rolling new drug application for COMP360 in treatment-resistant depression is nearing completion, with the final submission expected within two weeks and a launch targeted for the first half of 2027, subject to approval.
  • Third-quarter Research and Development spending was USD 23.5 million and selling, general and administrative expense was USD 33.0 million, mainly driven by commercial launch preparation.

Warrant Gain Narrows the Third-Quarter Loss

Compass Pathways (NASDAQ:CMPS) reported third-quarter 2026 results on November 3, 2026. The net loss was USD 9.8 million, or USD 0.07 per basic share and USD 0.31 per diluted share, but a USD 40.8 million non-cash gain on warrant liabilities did most of the work. Research and development plus selling, general and administrative costs came to USD 56.5 million, simple arithmetic on the two reported lines. Over nine months the net loss was USD 172.4 million, or USD 1.35 per share. The London-based company is developing COMP360, a psilocybin therapy for treatment-resistant depression and post-traumatic stress disorder. Because the gain is non-cash and tied to share-price movement in warrants, it does not indicate lower underlying spending.

NDA Timeline, Priority Voucher and 2027 Launch Plans

The company said its rolling new drug application for COMP360 in treatment-resistant depression is under review as it is submitted, and it expects to file the final portion within two weeks. No acceptance or action date has been disclosed. It also said a National Priority Voucher could shorten review to 1 to 2 months, while any launch in the first half of 2027 depends on approval by the US Food and Drug Administration. Separately, 52-week open-label data from the COMP005 study showed added benefit from an additional 25 mg dose and durability to one year.

Fast EPS Screen Meets a Non-Operating Base Effect

Published market data lists a 1 year EPS change of 109.03% and a price of about USD 8.36, down 2.68%, but neither could be matched to the filing and the screen date is not confirmed. The company is loss-making, so changes in loss per share reflect swings in warrant values, a non-operating item, rather than operating improvement. Debt rose to USD 51.0 million from USD 31.6 million at year-end 2025. Compass Pathways (NASDAQ:CMPS) faces regulatory delay, launch costs and possible dilution from further financing, and cash funding into 2028 depends on spending plans. Approval, if it comes, would also bring commercial costs that the current selling expense line only hints at.

Where Things Stand

Largely because of a non-cash accounting gain, not lower spending. The USD 9.8 million loss at Compass Pathways (NASDAQ:CMPS) was narrow because warrant liabilities fell in value by USD 40.8 million, while operating costs rose with launch preparation. The Balance Sheet is strong at USD 444.0 million of cash, with funding expected into 2028. The next dated catalyst is the final submission, expected within about two weeks of the November 3, 2026 release, followed by any agency word on review timing. A launch in the first half of 2027 remains conditional on approval.